Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.69)
# 168
Out of 5,245 analysts
140
Total ratings
55.12%
Success rate
43.1%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Upgrades: Buy | $3 → $9 | $4.53 | +98.68% | 3 | Apr 10, 2026 | |
| TBPH Theravance Biopharma | Maintains: Neutral | $14 → $17 | $16.37 | +3.85% | 3 | Apr 7, 2026 | |
| HROW Harrow | Reiterates: Buy | $74 → $65 | $33.00 | +96.97% | 5 | Apr 7, 2026 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $3 → $4 | $1.30 | +207.69% | 3 | Mar 25, 2026 | |
| CLYM Climb Bio | Initiates: Buy | $26 | $11.00 | +136.36% | 1 | Mar 24, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $22 | $7.03 | +212.94% | 3 | Mar 18, 2026 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $105 → $150 | $66.61 | +125.19% | 4 | Feb 23, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $90 → $108 | $76.94 | +40.37% | 6 | Jan 21, 2026 | |
| IRD Opus Genetics | Initiates: Buy | $9 | $4.26 | +111.27% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $39.75 | +5.66% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 → $40 | $25.61 | +56.19% | 2 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.72 | +154.24% | 1 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 → $16 | $9.21 | +73.72% | 20 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $560 | $517.26 | +8.26% | 13 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $38.87 | +41.50% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.38 | +740.34% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $2.90 | +520.69% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.40 | +257.14% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $14.13 | +41.54% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $18.64 | +87.77% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $74.95 | -49.30% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $30.89 | +210.78% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.26 | +19.05% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $6.11 | +2,191.33% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $4.04 | +2,127.72% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.11 | +5,044.69% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.78 | +180.90% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.74 | +3,184.67% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.45 | +382.76% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $0.6321 | +711,812.67% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.52 | +177,531.58% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.5801 | +248,133.06% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.50 | +60.00% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $88.56 | -55.96% | 2 | Mar 18, 2020 |
MacroGenics
Apr 10, 2026
Upgrades: Buy
Price Target: $3 → $9
Current: $4.53
Upside: +98.68%
Theravance Biopharma
Apr 7, 2026
Maintains: Neutral
Price Target: $14 → $17
Current: $16.37
Upside: +3.85%
Harrow
Apr 7, 2026
Reiterates: Buy
Price Target: $74 → $65
Current: $33.00
Upside: +96.97%
Lineage Cell Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $3 → $4
Current: $1.30
Upside: +207.69%
Climb Bio
Mar 24, 2026
Initiates: Buy
Price Target: $26
Current: $11.00
Upside: +136.36%
Arcturus Therapeutics Holdings
Mar 18, 2026
Initiates: Buy
Price Target: $22
Current: $7.03
Upside: +212.94%
Nektar Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $105 → $150
Current: $66.61
Upside: +125.19%
Cytokinetics
Jan 21, 2026
Maintains: Buy
Price Target: $90 → $108
Current: $76.94
Upside: +40.37%
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $4.26
Upside: +111.27%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $39.75
Upside: +5.66%
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $25.61
Upside: +56.19%
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $4.72
Upside: +154.24%
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $9.21
Upside: +73.72%
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $517.26
Upside: +8.26%
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $38.87
Upside: +41.50%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $2.38
Upside: +740.34%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $2.90
Upside: +520.69%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.40
Upside: +257.14%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $14.13
Upside: +41.54%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $18.64
Upside: +87.77%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $74.95
Upside: -49.30%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $30.89
Upside: +210.78%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.26
Upside: +19.05%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $6.11
Upside: +2,191.33%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $4.04
Upside: +2,127.72%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.11
Upside: +5,044.69%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.78
Upside: +180.90%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.74
Upside: +3,184.67%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.45
Upside: +382.76%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $0.6321
Upside: +711,812.67%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.52
Upside: +177,531.58%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.5801
Upside: +248,133.06%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $2.50
Upside: +60.00%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $88.56
Upside: -55.96%